• Home
  • Company
    • Overview
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Advisors
  • Pipeline
    • AMHR2 and GM102
    • GamaMabs Pharma Technology
  • News and Publications
    • Press Releases
    • Scientific Publications
    • Others Publications
    • Careers
  • Contact us

Archives

Phase 2 study results of murlentamab, a monoclonal antibody targeting the Anti-Müllerian-Hormone-Receptor II (AMHRII), acting through Tumor Associated Macrophage (TAM) engagement in advanced/metastatic colorectal cancers

  • 8 July 2019
  • Scientific publications

C201 – WCGIC 2019 Gamamabs poster #LBA-004 abstract 214_20190701

Post navigation

← A First-In-Human phase I trial of murlentamab, a first-in-class Anti-Müllerian-Hormone-Receptor II (AMHRII) monoclonal antibody acting through Tumor-Associated Macrophage engagement, as single agent and in combination with carboplatin and paclitaxel in AMHRII-expressing advanced/metastatic gynecological cancer patients
  • Terms of use
  • Privacy Policy
  • Legaly Notice
  • Contact
© copyright 2019 - GamaMabs - All rights reserved Website by PICTAO